Lwakatare J M, Maro E E, Mtulia I A
Department of Internal Medicine, Muhimbili Medical Centre, Dar es Salaam, Tanzania.
East Afr Med J. 1992 Dec;69(12):683-7.
Isradipine (Lomir) a new dihydropyridine calcium antagonist was evaluated for its efficacy, tolerability and safety among mild to moderate Tanzanian hypertensives. Twenty nine patients (7 males and 22 females), mean age 42.7 +/- 8.5 years entered active treatment phase, of the 16 week open label therapeutic trial. A mean decrease from base line in supine systolic blood pressure (SBP) of 17.6 mmHg (p < 0.001) and diastolic blood pressure (DBP) of 13.5 mmHg (p < 0.001) were achieved at the end of the study period. The corresponding changes from base line in standing SBP and DBP were 18 mmHg (p < 0.001) and 13.5 mmHg (p < 0.001) respectively. The efficacy was excellent or good in 84% and fair or none in 16% of the study patients. The tolerability of the drugs was excellent or good in 88.8% of patients, fair in 7.4% and bad in 3.8%. The mild side effects included headache, palpitations, tiredness and nocturia. But these improved with continued treatment. Isradipine (Lomir) at a dose of 1.25mg to 2.5mg twice daily is effective, safe and tolerable in mild to moderate hypertension.
伊拉地平（洛米）是一种新型二氢吡啶类钙拮抗剂，对坦桑尼亚轻度至中度高血压患者的疗效、耐受性和安全性进行了评估。29名患者（7名男性和22名女性），平均年龄42.7±8.5岁，进入了为期16周的开放标签治疗试验的积极治疗阶段。在研究期结束时，仰卧位收缩压（SBP）较基线平均下降17.6 mmHg（p<0.001），舒张压（DBP）下降13.5 mmHg（p<0.001）。站立位SBP和DBP较基线的相应变化分别为18 mmHg（p<0.001）和13.5 mmHg（p<0.001）。84%的研究患者疗效为优或良，16%为中或无疗效。88.8%的患者对药物耐受性为优或良，7.4%为中，3.8%为差。轻微副作用包括头痛、心悸、疲劳和夜尿症。但这些症状在持续治疗后有所改善。伊拉地平（洛米）每日两次，剂量为1.25mg至2.5mg，对轻度至中度高血压有效、安全且耐受性良好。
